Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement

Authors: Barbara Pienkowska-Grela, Grzegorz Rymkiewicz, Beata Grygalewicz, Renata Woroniecka, Paulina Krawczyk, Katarzyna Czyz-Domanska, Jan Walewski

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas.
Literature
1.
go back to reference Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.PubMedCrossRef Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.PubMedCrossRef
2.
go back to reference Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6. Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6.
3.
go back to reference Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4. Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4.
4.
go back to reference Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.PubMedCrossRef Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.PubMedCrossRef
5.
go back to reference Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.PubMedCrossRef Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.PubMedCrossRef
6.
go back to reference Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMed Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMed
7.
go back to reference Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11. Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11.
8.
go back to reference Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4.
9.
10.
go back to reference Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMed Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMed
11.
go back to reference Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.PubMedCrossRef Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.PubMedCrossRef
13.
go back to reference Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.PubMedCrossRef Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.PubMedCrossRef
14.
go back to reference Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005. Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005.
16.
go back to reference Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.PubMed Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.PubMed
17.
go back to reference Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.PubMedCrossRef Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.PubMedCrossRef
18.
go back to reference Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.PubMedCrossRef Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.PubMedCrossRef
19.
go back to reference Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.PubMed Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.PubMed
20.
go back to reference Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.PubMed Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.PubMed
Metadata
Title
Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement
Authors
Barbara Pienkowska-Grela
Grzegorz Rymkiewicz
Beata Grygalewicz
Renata Woroniecka
Paulina Krawczyk
Katarzyna Czyz-Domanska
Jan Walewski
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9614-0

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.